SCHEMBL848502

SCHEMBL848502

O=S(=O)(Nc1[c]nccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.48
IL1RN P18510 1/20 0.48
ERAP1 Q9NZ08 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
SLC40A1 Q9NP59 5/20 0.45
G6PD P11413 1/20 0.45
NFKBIA P25963 1/20 0.45
AGTR1 P30556 1/20 0.45
METAP2 P50579 1/20 0.45
METAP1 P53582 1/20 0.45
GLO1 Q04760 1/20 0.45
PAX8 Q06710 1/20 0.45
ATM Q13315 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319744 0.82 CA2 (0.54) MEN1KMT2ANFKBIATDP1NPSR1
SCHEMBL1902675 0.78 ALDH1A1 (0.55) ALDH1A1PKMSLC40A1TDP1TSHR
SCHEMBL2067604 0.77 GLO1 (0.41) KEAP1ALDH1A1GLO1LMNAHTT
SCHEMBL1902573 0.74 SLC40A1 (0.53) ALDH1A1PKMSLC40A1TSHRGAA
SCHEMBL1607675 0.73 KEAP1 (0.53) KEAP1IL1RNERAP1ALDH1A1MEN1
SCHEMBL5476179 0.72
SCHEMBL1599337 0.69 HTR6 (0.48) ALDH1A1MEN1PKMKMT2ATDP1
SCHEMBL332569 0.68 TSHR (0.70) KEAP1IL1RNERAP1ALDH1A1KMT2A
SCHEMBL70760 0.68 HSD17B10 (0.44) ALDH1A1MEN1KMT2AATMTDP1
SCHEMBL8582933 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616450-B1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2018-05-02 EP disclosed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
EP-1934191-B1 BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMA (US) 2012-03-28 EP disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed
US-5962682-A Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists HOFFMANN-LA ROCHE INC. (US) 1999-10-05 US disclosed
US-4902698-A Benzenesulphonamidopyridyl compounds which are useful as thromboxane A.sub.2 SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-02-20 US disclosed
US-4902698-A Benzenesulphonamidopyridyl compounds which are useful as thromboxane A.sub.2 SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 KEAP1 422/4885IL1RN 1789/4885ERAP1 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.